Quality of life and healthcare utilisation in cystic fibrosis: A multicentre study

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 571-577

  Bradley, Judy M ^a,b   Blume, Steven W ^e   Balp, Maria Magdalena ^f   Honeybourne, David ^d   Elborn, J Stuart ^b,c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e UNITED BIOSOURCE CORPORATION   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Health utility; Observational study

Indexed keywords

AZITHROMYCIN; COLISTIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SPIROMETRY; UNITED KINGDOM;

ADOLESCENT; ADULT; CYSTIC FIBROSIS; DELIVERY OF HEALTH CARE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84875257377     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00224911     Document Type: Article

References (32)

1. McCormick J, Green MW, Mehta G, et al. Demographics of the UK cystic fibrosis population: Implications for neonatal screening. Eur J Hum Genet 2002; 10: 583-590.
2. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29: 522-526.
3. Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136: 1554-1560.
4. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
5. Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
6. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
7. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
8. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.
9. Konstan MW, Geller DE, Minić P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 2010; 46: 230-238.
10. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10: 54-61.
11. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-1134.
12. Briesacher BA, Quittner AL, Fouavzi H, et al. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol 2011; 46: 770-776.
13. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009; 44: 989-996.
14. Weiner, JR Toy EL, Sacco P, et al. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: A review of the literature. Expert Opin Pharmacother 2008; 9: 751-766.
15. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
16. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioural function in cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 99-104.
17. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the Clinical Development of Medicinal Products for the Treatment of Cystic Fibrosis. www. ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/12/WC500017055.pdf Date last updated: May 12, 2011. Date last accessed: December 20, 2011.
18. Quittner A, Buu A,MesserMA, et al. Development and validation of the cystic fibrosis questionnaire in the United States: A health-related quality-of-life measure for cystic fibrosis. Chest 2005; 128: 2347-2354.
19. Rabin R, de Charro F. EQ-5D a measure of health status from the EuroQol group. Ann Med 2001; 33: 337-343.
20. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
21. Kind P. The EuroQol instrument: An index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Edn. Philadelphia, Lippincott-Raven Publishers, 1996; pp. 191-202.
22. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
23. MVH Group. The measurement and valuation of health. Final report on the modelling of valuation tariffs. York, Centre for Health Economics, 1995.
24. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-734.
25. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135: 1610-1618.
26. Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics 2009; 9: 2431-2439.
27. Johnson JA, Connolly M, Zuberbuhler P, et al. Health-related quality of life for adults with cystic fibrosis: A regression approach to assessing impact of recombinant human DNase. Pharmacotherapy 2000; 20: 1167-1174.
28. Polley L, Yaman N, Heaney L, et al. Impact of cough across different chronic respiratory diseases. Comparison of two coughspecific health-related quality of life questionnaires. Chest 2008; 134: 295-302.
29. Rutten-van Molken M, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117-1128.
30. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61: 1112-1120.
31. UK CF Registry. Annual Data Report 2008. http://www.cftrust. org.uk/aboutcf/publications/cfregistryreports/UK-CF-Registry-Annual-Data-Report- 2008.pdf Date last accessed. October 12, 2012.
32. Pressler T, Bohmova C, Conway S, et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 2011; 10: Suppl. 2, S75-S78.